News from Zyme and the companies we work with.

April 3, 20

Horizon Discovery expands cell-based CRISPR screening services

New arrayed B cell CRISPR knockout screening service strengthens support for development of therapeutics for diseases involving the immune system First in the market, this unique service complements the Company’s T cell screening service Cambridge, UK, 03 April 2020: Horizon … Continue reading →

April 2, 20

ERS Genomics and Axxam announce CRISPR/Cas9 license agreement to enhance discovery services

  DUBLIN, Ireland, and MILAN, Italy, 02 April 2020: ERS Genomics Limited (“ERS Genomics”), which was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Axxam S.p.A. (“Axxam”), a leading discovery biology … Continue reading →

April 2, 20

Cobra Biologics successfully completes key milestone in CombiGene’s epilepsy project CG01 with delivery of first DNA plasmid

Production method of plasmids developed and first plasmid produced for gene therapy drug candidate aimed at treating drug resistant focal epilepsy Keele, UK and Lund, Sweden, 2 April 2020: Cobra Biologics (“Cobra”), an international CDMO for biologics and pharmaceuticals, and … Continue reading →

April 2, 20

OXGENE and The Native Antigen Company Announce Collaboration to Increase COVID-19 Antigen Production for Diagnostic Kits and Vaccine Development

Oxford, UK, 02 April 2020: OXGENE™ and The Native Antigen Company today announced a collaboration to scale up production of SARS-CoV-2 (COVID-19) reagents by combining OXGENE’s proprietary Adenoviral Protein Machine Technology with The Native Antigen Company’s antigen development expertise. Together, … Continue reading →

April 1, 20

Optibrium and Intellegens achieve further success in Open Source Malaria initiative with in vitro validation of in silico generated compound

CAMBRIDGE, UK, 01 April, 2020 – Optibrium™, leading providers of software and services for drug discovery, and Intellegens™, a spin-out from the University of Cambridge with a unique Artificial Intelligence (AI) toolset, today announced they have reached a further significant … Continue reading →

March 31, 20

Horizon Discovery and Pharmahungary report positive early-stage results for novel micro-RNA therapeutic for ischemic heart diseases

Micro-RNA compound found suitable for further development following favorable pharmacokinetic and pharmacodynamic study results Cambridge, UK, and Budapest, Hungary, 31 March 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application … Continue reading →

March 31, 20

Cobra Biologics is proud to be part of a consortium to rapidly develop a COVID-19 vaccine

ChAdOx1 consortium, led by the Jenner Institute, working to produce adenoviral vaccine Fast-tracked clinical trials of ChAdOx1 to begin in April 2020 Keele, UK, 31 March 2020: Cobra Biologics (Cobra), an international CDMO for biologics and pharmaceuticals, today announced it … Continue reading →

March 30, 20

Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 vaccine

OPENCORONA consortium awarded €3 million funding by Horizon 2020 to support emergency research and development against the COVID-19 outbreak Keele, UK and Matfors, Sweden, 30 March 2020: Cobra Biologics (Cobra), an international CDMO for biologics and pharmaceuticals, and the Karolinska … Continue reading →

March 30, 20

TTP plc collaborates with SOLshare to develop next generation solar energy trading platform

Collaboration aims to achieve a ten-fold increase in power-sharing potential of SOLshare’s SOLbox energy trading platform Smart peer-to-peer micro-grid enables trading of excess solar energy in real-time—improving lives and economies of communities in developing countries Cambridge, UK and Dhaka, Bangladesh, … Continue reading →

March 30, 20

Owlstone Medical Appoints Neil Tween as Chief Financial Officer

Cambridge, UK, March 30 2020: Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine today announces the appointment of Neil Tween as its new Chief Financial Officer. Owlstone Medical is in the … Continue reading →